Abstract
Advice regarding the sequencing of AIs for treatment of early post-menopausal breast cancer can be confusing for patients. As nurses, we have a responsibility to interpret and communicate research findings in an attempt to facilitate decision-making for patients. But this can be difficult when there are no clear cut comparative trials for different AIs and their sequencing with tamoxifen. Nurses must offer advice on bone health, and the management of side effects such as menopausal symptoms. We must seek opportunities to enquire about the patient’s quality of life. In short, we must help our patients to understand the therapeutic potential, and also the drawbacks, of these new drugs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
